ASX:RAP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

Share Price & News

How has ResApp Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RAP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.0%

RAP

8.2%

AU Healthcare Services

-0.3%

AU Market


1 Year Return

-67.1%

RAP

4.3%

AU Healthcare Services

-6.9%

AU Market

Return vs Industry: RAP underperformed the Australian Healthcare Services industry which returned 4.2% over the past year.

Return vs Market: RAP underperformed the Australian Market which returned -7% over the past year.


Shareholder returns

RAPIndustryMarket
7 Day15.0%8.2%-0.3%
30 Day15.0%20.2%5.1%
90 Day-14.8%27.2%4.2%
1 Year-67.1%-67.1%4.7%4.3%-3.5%-6.9%
3 Year66.7%66.7%234.9%231.3%18.1%3.0%
5 Year42.0%42.0%254.4%242.3%44.2%15.1%

Price Volatility Vs. Market

How volatile is ResApp Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ResApp Health undervalued compared to its fair value and its price relative to the market?

12.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RAP is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: RAP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RAP is overvalued based on its PB Ratio (12.1x) compared to the AU Healthcare Services industry average (5.6x).


Next Steps

Future Growth

How is ResApp Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

100.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: RAP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RAP's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if RAP's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if RAP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RAP's Return on Equity is forecast to be very high in 3 years time (59.9%).


Next Steps

Past Performance

How has ResApp Health performed over the past 5 years?

-15.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RAP is currently unprofitable.

Growing Profit Margin: RAP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RAP is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.

Accelerating Growth: Unable to compare RAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-10.5%).


Return on Equity

High ROE: RAP has a negative Return on Equity (-121.01%), as it is currently unprofitable.


Next Steps

Financial Health

How is ResApp Health's financial position?


Financial Position Analysis

Short Term Liabilities: RAP's short term assets (A$6.7M) exceed its short term liabilities (A$1.6M).

Long Term Liabilities: RAP's short term assets (A$6.7M) exceed its long term liabilities (A$272.0K).


Debt to Equity History and Analysis

Debt Level: RAP is debt free.

Reducing Debt: RAP has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RAP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ResApp Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RAP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Tony Keating

5.25yrs

Tenure

AU$448,716

Compensation

Dr. Anthony Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement for En ...


CEO Compensation Analysis

Compensation vs Market: Tony's total compensation ($USD319.12K) is about average for companies of similar size in the Australian market ($USD277.57K).

Compensation vs Earnings: Tony's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Anthony Keating
CEO, MD & Director5.25yrsAU$448.72k1.32%
A$ 1.1m
Rob Keniger
Vice President of Technology0.25yrno datano data
Udantha Abeyratne
Scientific Founder & Consultantno datano datano data
Nicki Farley
Company Secretary7.92yrsno datano data
Clas Källander
Founder and Director of R&D of Cavidi ABno dataAU$108.72kno data
Brian Leedman
Vice President of Corporate Affairsno dataAU$190.18kno data
Paul Porter
Scientific Advisorno datano datano data

5.3yrs

Average Tenure

Experienced Management: RAP's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anthony Keating
CEO, MD & Director5.25yrsAU$448.72k1.32%
A$ 1.1m
Paul Porter
Scientific Advisorno datano datano data
Michael Stein
Non-Executive Director0.50yrno datano data
Roger Aston
Non-Executive Chairman5.25yrsAU$153.79kno data
Joseph Kvedar
Member of Industry Advisory Board1.33yrsno datano data
Christopher Ntoumenopoulos
Non-Executive Director5.75yrsAU$118.79kno data
Naomi Fried
Member of Industry Advisory Board1.33yrsno datano data
Philip Currie
Member of Scientific Advisory Board3.17yrsno datano data
Scott Claxton
Member of Scientific Advisory Board1.75yrsno datano data

2.5yrs

Average Tenure

Experienced Board: RAP's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.


Top Shareholders

Company Information

ResApp Health Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ResApp Health Limited
  • Ticker: RAP
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$87.184m
  • Shares outstanding: 758.12m
  • Website: https://www.resapphealth.com.au

Location

  • ResApp Health Limited
  • 100 Creek Street
  • Level 12
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RAPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2005
RAPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2005
NUGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2005

Biography

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respirator ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 10:33
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.